Details of the Drug Reposition

General Information of This Drug (ID: DM90XQC)

Drug Name
CTX001   DM90XQC
Drug Type
Gene therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Beta thalassemia DIS5RCQK 3A50.2 Phase 1/2 [1]
Sickle-cell disorder DISW25G5 3A51 Phase 1/2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03655678) A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent beta-Thalassemia. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT03745287) A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease. U.S. National Institutes of Health.